Slagle Financial LLC Has $1.95 Million Holdings in Amgen Inc. (NASDAQ:AMGN)

Slagle Financial LLC raised its position in Amgen Inc. (NASDAQ:AMGN) by 11.0% during the 4th quarter, HoldingsChannel.com reports. The firm owned 7,486 shares of the medical research company’s stock after purchasing an additional 742 shares during the period. Slagle Financial LLC’s holdings in Amgen were worth $1,951,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Blossom Wealth Management increased its holdings in Amgen by 3.5% in the fourth quarter. Blossom Wealth Management now owns 1,090 shares of the medical research company’s stock valued at $284,000 after purchasing an additional 37 shares during the period. Zullo Investment Group Inc. raised its stake in Amgen by 2.8% during the fourth quarter. Zullo Investment Group Inc. now owns 1,364 shares of the medical research company’s stock worth $356,000 after buying an additional 37 shares during the last quarter. Trillium Asset Management LLC boosted its position in Amgen by 4.2% during the fourth quarter. Trillium Asset Management LLC now owns 911 shares of the medical research company’s stock valued at $237,000 after acquiring an additional 37 shares during the last quarter. Prestige Wealth Management Group LLC boosted its position in shares of Amgen by 2.8% during the 3rd quarter. Prestige Wealth Management Group LLC now owns 1,387 shares of the medical research company’s stock valued at $447,000 after purchasing an additional 38 shares in the last quarter. Finally, Evermay Wealth Management LLC increased its holdings in Amgen by 1.5% in the fourth quarter. Evermay Wealth Management LLC now owns 2,650 shares of the medical research company’s stock worth $691,000 after purchasing an additional 38 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Insider Transactions at Amgen

In other news, EVP David M. Reese sold 25,225 shares of Amgen stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $304.44, for a total value of $7,679,499.00. Following the completion of the transaction, the executive vice president now owns 36,922 shares of the company’s stock, valued at $11,240,533.68. The trade was a 40.59 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 1,589 shares of the business’s stock in a transaction dated Wednesday, February 5th. The stock was sold at an average price of $304.47, for a total value of $483,802.83. Following the completion of the transaction, the senior vice president now directly owns 7,210 shares of the company’s stock, valued at approximately $2,195,228.70. This trade represents a 18.06 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 69,341 shares of company stock worth $20,644,335. 0.69% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

AMGN has been the topic of several research analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $324.00 target price on shares of Amgen in a research note on Friday, January 24th. Piper Sandler Companies restated an “overweight” rating and set a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. Bank of America boosted their target price on shares of Amgen from $275.00 to $294.00 and gave the stock an “underperform” rating in a research report on Wednesday, March 5th. UBS Group reissued a “hold” rating on shares of Amgen in a research note on Wednesday, February 12th. Finally, StockNews.com lowered shares of Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Two research analysts have rated the stock with a sell rating, ten have given a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $314.04.

Amgen Stock Performance

Shares of NASDAQ AMGN opened at $305.77 on Friday. Amgen Inc. has a 1-year low of $253.30 and a 1-year high of $346.85. The stock has a market cap of $164.26 billion, a price-to-earnings ratio of 40.50, a P/E/G ratio of 2.63 and a beta of 0.53. The stock’s 50-day moving average is $300.39 and its 200 day moving average is $298.51. The company has a current ratio of 1.26, a quick ratio of 0.95 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, topping the consensus estimate of $5.04 by $0.27. Amgen had a return on equity of 176.32% and a net margin of 12.24%. On average, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be given a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a yield of 3.11%. The ex-dividend date is Friday, May 16th. Amgen’s payout ratio is 126.09%.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.